FINAL SCIENTIFICPROGRAMME

AGENDA

8:30 AM 8:45 AM

8:45 AM 9:00 AM

9:00 AM 9:15 AM

9:15 AM 9:30 AM

9:30 AM 9:45 AM

9:45 AM 10:00 AM

10:00 AM 10:40 AM

10:40 AM 11:00 AM

11:00 AM 11:15 AM

11:15 AM 11:40 AM

11:40 AM 12:00 PM

12:00 PM 1:00PM

How I do it Videos: 1. Dissection of right subdiaphragmatic peritoneum & hepatoduodenal ligament2. Mesenteric dissection3. PIPAC4. Dissection around the stomach

Intraperitoneal chemotherapy-types, techniques, tips

Choice of drugs and carriersolutions for intraperitonealchemotherapy

Port directed chemotherapyin peritoneal malignancies

Speaker Chairpersons

PaulSugarbaker

FaheezMohamed

H Ishigami

TSGanesan,SG Ramanan,PrashanthPenumadu

Kalpana B, Pankaj Pandey

Preoperative optimisation ofpatients undergoing CRS/HIPEC

John Bell

Integrating ERAS in a CRS/HIPEC service

Rehabilitation and quality of lifeafter CRS/HIPEC

Optimal management of peritoneal metastasis ingastric cancer

PIPAC-1: Science, indications,technique

Prevention of peritonealmetastasis in gastric cancer

PIPAC-2: safety, efficacy, trials

Tea Break

MartinHubner

Ignace deHingh

MartinHubner

MartinHubner

Ninad K,Ashwin D’Souza

Ayyappan SHemanth Raj

SanjeevDayal

Sanket MehtaMartin HubnerPaulSugarbaker

Day 1

HironoriIshigami

HironoriIshigami

Hemanth Raj E,SM ChandramohanShivendra Singh

Hemanth Raj E,SM ChandramohanShivendra Singh

1:00 PM 2:00 PM

2:00 PM 2:20 PM

2:20 PM 2:45 PM

2:45 PM 3:00 PM

3:00 PM 3:15 PM

3:15 PM 4:00 PM

4:15 PM 5:00 PM

5:00 PM 5:30 PM

5:30PM 6:20 PM

6:20 PM 6:40 PM

6:40 PM 7:00 PM

Current pathological classification of PMP

Management of tumorsof theappendix

Norman Carr

FaheezMohamed

SanjeevDayal

SanjeevDayal

Moderator: Rohin MittalPanelists: Paul SugarbakerNorman Carr, Faheez MohamedAvanish Saklani, Sanket Mehta

Moderator: Sanket Mehta Panelists: Sanjeev Dayal,Hironori Ishigami, HaritChaturvediSVS Deo, Ignace de HinghRobin Thambudorai

Lunch Break

Tea Break

Shirley S,SVS Deo,VikasMahajan

Fertility issues related to thesurgical management ofperitoneal malignancy

What’s new in PMP- smallbowel transplantation

Case discussion: Appendicularmucinous neoplasms

Panel discussion: Challenges instarting a peritonealmalignancy program

Learning curve and minimisingmorbidity in CRS/HIPEC

Shivendra Singh,Ayyappan SSomasekar S P

4:00 PM 4:15 PM

Inauguration and Journal release

Dinner

Training in peritoneal malignancies:Young Indian Perspective

ESPSO fellowship Basingstoke experience ICRETT fellowship Japanese experience

Snita Sinu kumarRohin MittalAshwin RajagopalAruna Prabhu

I de Hingh,AshvinRangole,Sethna K

FaheezMohamed

PaulSugarbaker

F Quenet,Sanket Mehta

HIPEC for rare tumors

7:00 PM 9:00 PM

Day 1

Hall 2- Breakout sessions

1:00 PM 2:00 PM

2:00 PM 2:30 PM

2:30 PM 3:00 PM

3:00 PM 3:20 PM

3:20 PM 3:50 PM

3:50 PM 4:10 PM

4:30 PM 4:50 PM

4:50 PM 5:15 PM

10:00 AM 1:00 PM

Pseudomyxoma peritonei and appendicularneoplasia: a practical approach to histologicaldiagnosisInteractive session with live slide discussionsHighlights:- Recent histological classification of appendicular neoplasia and pseudomyxoma peritonei- Grading of pseudomyxoma peritonei- Differential diagnosis of LAMN

Welcome, preoperative assessment andPrehabilitation

Anaesthetic management of CRS and HIPEC

Anaesthetic implications of chemotherapeuticdrugs used in HIPEC

PIPAC for anaesthesiologists

Post-operative management of theCRS/HIPEC patient

Panel discussion on debatable issuesin peri-op care of CRS-HIPEC

Hemodynamic monitoring and Fluid Management

Lead Faculty: Norman Carr,Shirley S

Kalpana B

John Bell

John Bell

Rakesh Garg

Speaker

Lunch Break

Tea Break

PATHOLOGY

ANAESTHESIOLOGY

Martin Hubner

Sudipta Mukherjee

4:10 PM 4:30 PM

Day 1

Moderator:Meenakshi VV

Nitin BhorkarRajesh HolaluJohn Bell

Tea Break

8:00 AM 9:00 AM

9:00 AM 10:00 AMCase discussion with theexperts - difficult casescenarios

10:00AM 10:20 AM

10:20 AM 10:40 AM OVHIPEC trial results

10:40 AM 11:00 AM

11:00 AM 11:30 AM

Best of India at PSOGI 20181. Failure-to-rescue following CRS and hipec is determined by the type of complication 2. Time to adjuvant chemotherapy & impact on survival in advanced ovarian malignancies3. Extent of peritoneal disease in lower abdomen and it’s relation to nodal disease in stage 3c epithelial ovarian cancer.4. CRS and HIPEC in stage III EOC comparison of oncological outcomes with CRS + IV and CRS+ IP chemotherapy5. Rectal resection does not increase the major morbidity in patients undergoing CRS & hipec for colorectal pm6. Can the negative prognostic impact of a poor/ moderate response to neoadjuvant chemotherapy be offset by a complete interval cytoreductive surgery in patients with advanced epithelial ovarian, fallopian tube and primary peritoneal cancer?

F QuenetRay MD

Ignace de HinghMartin HubnerF QuenetFaheez Mohamed

Amita MaheswariVijaykumar DKGanesan TS

Speaker Chairpersons

TBA

Ignace dehingh

PaulSugarbaker

Rationale and results to datefor treatment of primary &recurrent ovarian cancer

Debate: Extent of peritonectomyfor ovarian cancer

Total parietalAditiBhatt Selective(involved)Vijaykumar DK

Paul Sugarbaker,Hemanth Raj E

Day 2

11:30 AM 12:00 PM

12:00 PM 12:15 PM

12:15 PM 12:30 PM

12:30 PM 1:00 PM

1:00 PM 2:00 PM

2:00 PM 2:30 PM

2:30 PM 2:50 PM

2:50 PM 3:00 PM

3:00 PM 3:15 PM

3:15 PM 3:30 PM

3:30 PM 4:15 PM

4:15 PM 4:30 PM

4:30 PM

How I manage ovarian cancerwith peritoneal metastasis?Initial presentation

Recurrent Ovarian cancer

Is there still a role for portdirected IP chemo in ovariancancer?

Somasekar SP

AbrahamPeedicayil

AmitaMaheswari

Firoz Rajan

Paul Sugarbaker,Hemanth Raj E

EPIC in ovarian cancers

Videos:Pelvic peritonectomyIntraperitoneal port placement

AbrahamPeedicayil,Rejiv RVikas Mahajan

Avanish Saklani,Martin Hubner,Venkatraman R

Aditi BhattSomasekar SP

For-FrancoisQuenetAgainst-Ignace de Hingh

Lunch Break

Debate: Systemic therapy in thecontext of CRS in CRCperitoneal metastasis- forand against

Results of PRODIGE 7 & PROPHYLOCHIP trials

FrancoisQuenet

Ignace deHingh

Paul SugarbakerFaheez Mohamed

Putting PRODIGE-7 inperspective: why thisshould not be the end ofCRS and HIPEC in colorectalperitoneal metastasis

Comments on colorectalHIPEC trials

PaulSugabaker

Open house

Professional collaboration inperitoneal malignancies: - PSOGI- Dutch registry- RENAPE experience- Indian HIPEC registry

Looking through the crystalball-what does the future holdfor peritoneal surfacemalignancies?

Valedictory

Paul SugarbakerI de HinghF QuenetAditi Bhatt

PaulSugarbaker

SVS DeoHemanth Raj E

Day 2

We Thank Our Sponsors

GUFICBIOSCIENCES LIMITED

ThermaSolutions

INSTRUMENT CORPORATION

FRESENIUSKABI

INDIA

THANK YOU...FOR PARTICIPATION